WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H526929
CAS#: 167006-13-5
Description: KRH-594, also known as WK-1492; WK-14922K, is a potent, specific and insurmountable AT1 receptor antagonist. KRH-594 prevents end-organ damage in stroke-prone spontaneously hypertensive/Izm rats. KRH-594 ameliorates nephropathy and hyperlipidaemia in diabetic spontaneously hypertensive rats.
Hodoodo Cat#: H526929
Name: KRH-594 free acid
CAS#: 167006-13-5
Chemical Formula: C25H23N7O3S
Exact Mass: 501.16
Molecular Weight: 501.565
Elemental Analysis: C, 59.87; H, 4.62; N, 19.55; O, 9.57; S, 6.39
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: KRH-594 free acid; WK-1492; WK-14922K; WK1492; WK14922K.
IUPAC/Chemical Name: (Z)-2-((3-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-5-ethyl-1,3,4-thiadiazol-2(3H)-ylidene)carbamoyl)cyclopent-1-ene-1-carboxylic acid
InChi Key: UFZKNCXXIFQTNB-QPLCGJKRSA-N
InChi Code: InChI=1S/C25H23N7O3S/c1-2-21-29-32(25(36-21)26-23(33)19-8-5-9-20(19)24(34)35)14-15-10-12-16(13-11-15)17-6-3-4-7-18(17)22-27-30-31-28-22/h3-4,6-7,10-13H,2,5,8-9,14H2,1H3,(H,34,35)(H,27,28,30,31)/b26-25-
SMILES Code: O=C(C1=C(C(O)=O)CCC1)/N=C2SC(CC)=NN\2CC3=CC=C(C4=CC=CC=C4C5=NN=NN5)C=C3
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info: Related CAS# 167006-13-5 (KRH-594 free acid ) 169328-25-0 (KRH-594 potassium)
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 501.57 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Komiyama J, Yang XP, Chiba S. Prejunctional AT(1) receptor subtype-dependent modification of neurotransmitter releases in canine isolated splenic arteries. Auton Autacoid Pharmacol. 2003 Oct-Dec;23(5-6):297-305. PubMed PMID: 15255814.
2: Yang XP, Chiba S. Angiotensin II receptor subtypes involved in the modulation of purinergic and adrenergic vasoconstrictions to periarterial electrical nerve stimulation in the canine splenic artery. J Cardiovasc Pharmacol. 2003 Jan;41 Suppl 1:S49-52. PubMed PMID: 12688396.
3: Inada Y, Nakane T, Chiba S. Binding of KRH-594, an antagonist of the angiotensin II type 1 receptor, to cloned human and rat angiotensin II receptors. Fundam Clin Pharmacol. 2002 Aug;16(4):317-23. PubMed PMID: 12570021.
4: Inada Y, Tazawa S, Murakami M, Akahane M. KRH-594, a new angiotensin AT1 receptor antagonist, prevents end-organ damage in stroke-prone spontaneously hypertensive/Izm rats. Clin Exp Pharmacol Physiol. 2001 Mar;28(3):206-11. PubMed PMID: 11207677.
5: Inada Y, Murakami M, Tazawa S, Akahane M. KRH-594, a new angiotensin AT1 receptor antagonist, ameliorates nephropathy and hyperlipidaemia in diabetic spontaneously hypertensive rats. Clin Exp Pharmacol Physiol. 2000 Apr;27(4):270-6. PubMed PMID: 10779124.
6: Inada Y, Murakami M, Kaido K, Nakao K. Effects of the new angiotensin II type 1 receptor antagonist KRH-594 on several types of experimental hypertension. Arzneimittelforschung. 1999 Jan;49(1):13-21. PubMed PMID: 10028373.
7: Tazawa S, Nakane T, Chiba S. Angiotensin II type 1 receptor blockade prevents up-regulation of angiotensin II type 1A receptors in rat injured artery. J Pharmacol Exp Ther. 1999 Feb;288(2):898-904. PubMed PMID: 9918604.
8: Tamura K, Okuhira M, Amano H, Inokuma K, Hirata T, Mikoshiba I, Hashimoto K. Pharmacologic profiles of KRH-594, a novel nonpeptide angiotensin II-receptor antagonist. J Cardiovasc Pharmacol. 1997 Nov;30(5):607-15. PubMed PMID: 9388043.
9: Murakami M, Inada Y, Tazawa S, Nakao K, Komatsu H. Effects of the new angiotensin receptor antagonist dipotassium (Z)-2-[[5-ethyl-3-[2'-(1H-tetrazol-5-yl)biphenyl-4-yl] methyl-1,3,4-thiadiazoline-2-ylidene]aminocarbonyl]-1-cy clopentencarbox ylate on experimental cardiac hypertrophy and acute left ventricular failure. Arzneimittelforschung. 1997 Oct;47(10):1099-103. PubMed PMID: 9368701.
10: Tamura K, Okuhira M, Mikoshiba I, Hashimoto K. In vitro pharmacological properties of KRH-594, a novel angiotensin II type 1 receptor antagonist. Biol Pharm Bull. 1997 Aug;20(8):850-5. PubMed PMID: 9300129.